Australia markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.2271-0.0113 (-4.74%)
As of 02:35PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E 51.55
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.15
52-week change 3-91.05%
S&P500 52-week change 3-7.13%
52-week high 33.0500
52-week low 30.1310
50-day moving average 30.1934
200-day moving average 30.6346

Share statistics

Avg vol (3-month) 3400.16k
Avg vol (10-day) 3243.04k
Shares outstanding 527.98M
Implied shares outstanding 6N/A
Float 824.33M
% held by insiders 17.93%
% held by institutions 158.40%
Shares short (12 Jan 2023) 4219.56k
Short ratio (12 Jan 2023) 40.59
Short % of float (12 Jan 2023) 41.22%
Short % of shares outstanding (12 Jan 2023) 40.78%
Shares short (prior month 14 Dec 2022) 430.33k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 317 Nov 2019
Ex-dividend date 4N/A
Last split factor 22:3
Last split date 314 Apr 2020

Financial highlights

Fiscal year

Fiscal year ends 29 June 2022
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-24,126.03%

Management effectiveness

Return on assets (ttm)-61.24%
Return on equity (ttm)-121.35%

Income statement

Revenue (ttm)73k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)64k
EBITDA -17.45M
Net income avi to common (ttm)-18.26M
Diluted EPS (ttm)-2.1720
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)16.53M
Total cash per share (mrq)0.59
Total debt (mrq)749k
Total debt/equity (mrq)5.12
Current ratio (mrq)5.67
Book value per share (mrq)0.57

Cash flow statement

Operating cash flow (ttm)-15.67M
Levered free cash flow (ttm)-8.31M